New AstraZeneca drug combo extends survival in tough lung cancer cases, offering a chemo alternative.
AstraZeneca announced positive late-stage trial results for a two-drug combination treating a resistant form of lung cancer. The combo pairs Tagrisso, an established lung cancer pill, with Orpathys, a newer drug targeting the MET protein that causes ...
